CN104093454A - 治疗阿耳茨海默氏病的组合物和方法 - Google Patents

治疗阿耳茨海默氏病的组合物和方法 Download PDF

Info

Publication number
CN104093454A
CN104093454A CN201280066632.7A CN201280066632A CN104093454A CN 104093454 A CN104093454 A CN 104093454A CN 201280066632 A CN201280066632 A CN 201280066632A CN 104093454 A CN104093454 A CN 104093454A
Authority
CN
China
Prior art keywords
approximately
antibody
disease
hyperimmune preparation
hyperimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280066632.7A
Other languages
English (en)
Chinese (zh)
Inventor
N·R·卡什曼
G·马克拉蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Cangene US Inc
Original Assignee
University of British Columbia
Cangene US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Cangene US Inc filed Critical University of British Columbia
Publication of CN104093454A publication Critical patent/CN104093454A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201280066632.7A 2011-11-10 2012-11-12 治疗阿耳茨海默氏病的组合物和方法 Pending CN104093454A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161558430P 2011-11-10 2011-11-10
US61/558,430 2011-11-10
US201261589809P 2012-01-23 2012-01-23
US61/589,809 2012-01-23
US201213582308A 2012-08-31 2012-08-31
US13/582,308 2012-08-31
PCT/US2012/064722 WO2013071267A1 (en) 2011-11-10 2012-11-12 Compositions and methods for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
CN104093454A true CN104093454A (zh) 2014-10-08

Family

ID=48290671

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280066632.7A Pending CN104093454A (zh) 2011-11-10 2012-11-12 治疗阿耳茨海默氏病的组合物和方法

Country Status (8)

Country Link
EP (1) EP2780082A4 (ru)
CN (1) CN104093454A (ru)
AU (1) AU2012335014A1 (ru)
CA (1) CA2855669A1 (ru)
EA (1) EA201491851A1 (ru)
HK (1) HK1201771A1 (ru)
SG (1) SG11201403272YA (ru)
WO (1) WO2013071267A1 (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847504A (zh) * 2015-05-18 2018-03-27 斯奈普泰克发展有限责任公司 淀粉状蛋白β的加兰他敏清除
CN112661828A (zh) * 2021-01-15 2021-04-16 武汉大学 一种突触素的抗原肽及其抗体与应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012022229A2 (pt) 2010-03-03 2016-07-05 Univ British Columbia epítopo beta amilóide epecíficio para oligômero e anticorpos
EP3102611A4 (en) * 2014-02-03 2017-08-23 Cangene Corporation Humanized beta-amyloid binding molecules and uses thereof
WO2016008047A1 (en) * 2014-07-14 2016-01-21 Cangene Corporation Cyclic peptide vaccination for treatment of amyloid beta-related disorders
WO2017079833A1 (en) * 2015-11-09 2017-05-18 The University Of British Columbia Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
EP3374382A4 (en) * 2015-11-09 2019-05-15 The University Of British Columbia BETA-AMYLOID EPITOPES AND ASSOCIATED SELECTIVE CONFORMATIONAL ANTIBODIES
US20180346534A1 (en) * 2015-11-09 2018-12-06 The University Of British Columbia C-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
EP3374383A4 (en) * 2015-11-09 2019-05-15 The University Of British Columbia BETA-AMYLOID EPITOPES AND ASSOCIATED ANTIBODIES
WO2017079831A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US10259865B2 (en) * 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102112488A (zh) * 2008-07-01 2011-06-29 由卫生福利和体育大臣代表的荷兰王国 抗淀粉样折叠中间体的疫苗
WO2011100292A1 (en) * 2010-02-09 2011-08-18 Bristol-Myers Squibb Company Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards
WO2011106885A1 (en) * 2010-03-03 2011-09-09 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110306605A1 (en) * 2008-12-22 2011-12-15 Sloan-Kettering Institute For Cancer Research Coumarin-based compounds for the treatment of alzheimer's disease and cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102112488A (zh) * 2008-07-01 2011-06-29 由卫生福利和体育大臣代表的荷兰王国 抗淀粉样折叠中间体的疫苗
WO2011100292A1 (en) * 2010-02-09 2011-08-18 Bristol-Myers Squibb Company Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards
WO2011106885A1 (en) * 2010-03-03 2011-09-09 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRIAN O ET AL.: "Human plasma contains cross-reactive Aβ conformer-specific IgG antibodies", 《BIOCHEMISTRY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847504A (zh) * 2015-05-18 2018-03-27 斯奈普泰克发展有限责任公司 淀粉状蛋白β的加兰他敏清除
CN112661828A (zh) * 2021-01-15 2021-04-16 武汉大学 一种突触素的抗原肽及其抗体与应用

Also Published As

Publication number Publication date
EP2780082A4 (en) 2015-08-05
EP2780082A1 (en) 2014-09-24
AU2012335014A1 (en) 2014-06-19
CA2855669A1 (en) 2013-05-16
SG11201403272YA (en) 2014-08-28
EA201491851A1 (ru) 2015-12-30
HK1201771A1 (en) 2015-09-11
WO2013071267A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
CN104093454A (zh) 治疗阿耳茨海默氏病的组合物和方法
US20140314773A1 (en) Compositions and methods for treating alzheimer's disease
CN102936287A (zh) 能够特异性结合Aβ 寡聚体的抗体及其应用
CN102596997A (zh) 特异性结合Aβ寡聚体的抗体及其用途
CN104040342A (zh) 抗α-共核蛋白抗体诊断脑中的α-共核蛋白的升高水平的用途
CA3036592A1 (en) Antibodies to human alpha-synuclein
US20080057057A1 (en) Anti-Lipid Rafts Antibodies
CN102596999B (zh) 识别淀粉样蛋白β的转角结构的抗体
US20170198021A1 (en) Methods of treating diabetes and compositions capable of same
CN101466732A (zh) Iv型胶原样免疫反应性多肽
US20160280742A1 (en) Compositions and Methods for Treating Alzheimer's Disease
Martin et al. Mechanism, and treatment of anti-CV2/CRMP5 autoimmune pain
Feldmann Development of a Novel Adult Mouse Model and in Vitro Testing of Signaling Pathway Inhibitors in Pemphigus Vulgaris
US20170096476A1 (en) Methods and compositions related to amyloid-beta-42 oligomers
AU2013205000B2 (en) Oligomer-specific amyloid beta epitope and antibodies
WO2016008047A1 (en) Cyclic peptide vaccination for treatment of amyloid beta-related disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141008